Tuesday February 24, 2026
If there’s a throughline this week, it’s strategic tightening — large strategics consolidating, AI embedding into core platforms, and capital concentrating around infrastructure and leverage… but, one quick thing before we get started:
Today, our community lost Afu Fiefia after his courageous four-year battle with Ewing sarcoma. Just 19 years old, Afu left a lasting imprint on everyone who knew him — and on the broader community that rallied around him throughout his fight.
Our thoughts and prayers are with his family and loved ones during this difficult time.
You can learn more about Afu’s story here. His family has established a GoFundMe to help ease the financial strain of the past four years. If you feel moved to support them, you can contribute here:
https://www.gofundme.com/f/help-afu-fiefia-overcome-cancers-return
8 things to watch this week:
1. 🧪 Haemonetics Receives FDA Clearance for NexSys PCS with Persona Plus
FDA clearance for Persona Plus technology inside Haemonetics’ plasma platform reinforces a broader shift: operational AI embedded into revenue-generating systems. Workflow optimization is now a competitive differentiator — not a feature add.
PR Newswire
2. 🏥 FDA Approves Allurion’s PMA Application
Allurion secures PMA approval — the FDA’s highest regulatory bar. In a disciplined capital market, PMA-backed platforms carry stronger acquisition credibility and pricing leverage.
Medical Device Network
3. 🤖 Medtronic Moves to Acquire CathWorks to Expand AI-Driven Coronary Diagnostics
Medtronic continues building AI depth through acquisition rather than internal experimentation. Expect more strategics to buy validated, workflow-integrated algorithms instead of building from scratch.
The Healthcare Technology Report
4. 🔎 Commercial Strategy for Medical Device Leaders by RŌG Health
Medical device companies don’t struggle because they can’t build.
They struggle when commercialization, reimbursement, adoption, and capital strategy aren’t aligned.
RŌG Health helps device and medtech leaders pressure-test commercial readiness before major milestones — fundraising, FDA clearance, market expansion, or strategic partnerships.
We clarify the story, surface risk, and sharpen positioning — before execution capital is deployed. Strategic clarity for companies building in regulated markets.
5. 🔬 Quantum Surgical Announces Acquisition of NeuWave
Quantum Surgical expands its robotics footprint through NeuWave’s ablation technology. Platform adjacency remains the dominant M&A strategy — deepen the ecosystem, control more of the procedure.
Yahoo Finance
6. 🏛 Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson
J&J is reportedly exploring a major asset sale as portfolio optimization continues post-spinoff. Expect sharper focus, fewer middle-tier assets, and more aggressive capital allocation moves from large-cap medtech.
MSN / Bloomberg
7. 🛡 Censinet Unveils Censinet GRC AI and Platform Innovations at ViVE 2026
Censinet introduces AI-driven governance, risk, and compliance tooling. As devices become software-enabled and cloud-connected, cybersecurity and vendor risk oversight are increasingly board-level priorities.
Citizen Times
8. 💰 Handl Health Secures $14M Series A to Reform Healthcare Access and Affordability
Handl Health raises capital to expand healthcare pricing and claims intelligence. Employer and payer cost pressure continues shaping reimbursement dynamics — and ultimately, med device margin structures.
PR Newswire
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.